Green Lifescience Co., Ltd. (KOSDAQ: 114450)

Market Cap	45.40B
Revenue (ttm)	24.60B
Net Income (ttm)	-12.04B
Shares Out	20.00M
EPS (ttm)	-611.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,538,358
Open	2,110.00
Previous Close	2,105.00
Day's Range	2,110.00 - 2,690.00
52-Week Range	1,613.00 - 4,545.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Green Lifescience

Green Lifescience Co., Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals and pesticides; and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, a piperacillin antibiotic intermediate; N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw drug, and AM19, an antibiotic intermediate, as well as 1,1'-carbony...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 70
• Stock Exchange: KOSDAQ
• Ticker Symbol: 114450

Financial Performance

In 2023, Green Lifescience's revenue was 22.37 billion, a decrease of -38.72% compared to the previous year's 36.50 billion. Losses were -16.36 billion, 364.0% more than in 2022.